此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Emapalumab 预防 CAR-T 细胞相关毒性

2026年10月1日 更新者:Marcela V. Maus, M.D.,Ph.D.

Emapalumab 预防 CAR-T 细胞相关毒性的 2 期试验

This research study involves assessing the impact of emapalumab as preventative management of CAR-T related cytokine release syndrome in participants with Non-Hodgkin's lymphoma (NHL).

The research study involves the following study interventions:

  • Fludarabine and cyclophosphamide (Lymphodepleting Chemotherapy)
  • Axicabtagene Ciloleucel or Lisocabtagene Maraleucel
  • Emapalumab

研究概览

详细说明

This is a phase 2 multi-center, open label study that is evaluating the safety and efficacy of emapalumab in preventing toxicities associated with FDA Approved, CD19-directed CAR-T in subjects with second- or third-line large B-cell non-Hodgkin's lymphoma.

A phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. "Investigational" means that the drug is being studied.

The U.S. Food and Drug Administration (FDA) has not approved emapalumab for the participants specific disease, but it has been approved for other uses.

The U.S. FDA has approved axicabtagene ciloleucel and lisocabtagene maraleucel for the participants specific disease.

This research study procedures include screening for eligibility, study treatment including collection of T cells (leukapheresis), lymphodepleting chemotherapy, treatment with emapalumab and axicabtagene ciloleucel or lisocabtagene maraleucel, and follow-up evaluations.

Once study treatment is completed, the participants will be followed for up to 24 months.

It is expected that about 28 people will take part in this research study.

研究类型

介入性

注册 (估计的)

28

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Massachusetts
      • Boston、Massachusetts、美国、02114
        • 招聘中
        • Massachusetts General Hospital
        • 首席研究员:
          • Matthew Frigault, MD
        • 接触:
      • Boston、Massachusetts、美国、02215

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Or adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.

  • At least 1 measurable lesion per Lugano at time of screening.

  • Age 18 or older

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

  • Adequate renal, hepatic, pulmonary and cardiac function defined as:

    • ANC ≥1000/uL
    • Platelet count ≥50,000/uL
    • Absolute lymphocyte count ≥100/uL
    • Creatinine clearance (as estimated by Cockcroft Gault or CKD-EPI) ≥ 30 mL/min
    • Serum ALT/AST ≤2.5 per institutional ULN
    • Total bilirubin ≤1.5 mg/dl, except in subjects with Gilbert's syndrome.
    • Cardiac ejection fraction ≥ 40%, no clinically significant pericardial effusion, and no clinically significant ECG findings
    • Baseline oxygen saturation >92% on room air.
  • Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).

  • Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of malignancy other than nonmelanoma skin cancer or carcinoma in situ (e.g. cervix, bladder, breast) or follicular lymphoma unless disease free for at least 3 years.

  • Autologous stem cell transplant within 6 weeks of planned CAR-T infusion.

  • History of allogeneic stem cell transplantation.

  • Presence of uncontrolled fungal, bacterial, viral, or other infection at time of screening.

  • Known history of acute or chronic active hepatitis B or C infection. Subjects with history of hepatitis infection must have cleared their infection as determined by standard serological and genetic testing per current Infectious Diseases Society of America (IDSA) guidelines.

    • Patients should also be negative for latent Tb, CMV (NAT), EBV (NAT) and adenovirus (NAT) by PCR testing.
  • No evidence of active CNS disease regardless of prior CNS history.

  • History or presence of CNS disorder such as seizure disorder, cerebrovascular ischemia/hemorrhage within 6 months of enrollment.

  • History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment.

  • History of symptomatic pulmonary embolism within 3 months of enrollment; ongoing anticoagulation is allowed if beyond 3 months.

  • Any medical condition likely to interfere with assessment of safety or efficacy of study treatment.

  • History of allergic reactions or severe immediate hypersensitivity reaction to any of the agents used in this study or compounds of similar chemical or biologic composition.

  • Females who are pregnant or breastfeeding or female or male participants who are not willing to practice birth control from the time of consent through 6 months after the completion of CAR-T

  • In the investigators judgment, the subject is unlikely to complete all protocol-required study visits or procedures, including follow-up visits, or comply with the study requirements for participation.

  • History of autoimmune disease requiring ongoing systemic immunosuppression. Steroids are allowed up to 5mg predinosine-equivalent for adrenal insufficiency.

  • Receipt of a BCG vaccine within 12 weeks prior to Screening.

  • Receipt of a live or attenuated live (other than BCG) vaccine within 4 weeks prior to screeing.

  • Participants who are receiving any other investigational agents for this condition.

  • Patients anticipated to require canakinumab, JAK inhibitors, TNF inhibitors, and tocilizumab for non-CAR-T management of baseline autoimmune/inflammatory disease at the time of emapalumab initiation.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cohort 1a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

其他名称:
  • 游戏方
  • 人抗干扰素γ(IFNγ)单克隆抗体

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

实验性的:Cohort 1b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

FDA Approved CAR-T will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

其他名称:
  • 游戏方
  • 人抗干扰素γ(IFNγ)单克隆抗体

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

Corticosteroid

实验性的:Cohort 2a

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Patients will receive emapalumab 3mg/kg on day -1.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

An interferon gamma (IFNγ) blocking antibody

其他名称:
  • 游戏方
  • 人抗干扰素γ(IFNγ)单克隆抗体

Alkylating agent

Purine antagonist antimetabolite

Autologous treatment

实验性的:Cohort 2b

Leukapheresis will happen within approximately 5 days of eligibility confirmation.

Lymphodepleting Chemotherapy with cyclophosphamide and fludarabine will occur once a day for 3 days (Days -5 through Day -3) by intravenous infusion over about 2-4 hours.

Lisocabtagene maraleucel will be given once on Day 0 by intravenous infusion over about 30 minutes.

Patients will start dexamethasone 10mg PO daily starting on day 0 through day +2.

Patients will receive emapalumab 3mg/kg on day +1.

An interferon gamma (IFNγ) blocking antibody

其他名称:
  • 游戏方
  • 人抗干扰素γ(IFNγ)单克隆抗体

Alkylating agent

Purine antagonist antimetabolite

Corticosteroid

Autologous treatment

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Incidence of grade 2+ CRS per ASTCT
大体时间:Day -1 to 24 months post treatment

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). All participants will be monitored and assessed for grade 2+ cytokine release syndrome (CRS) for 24 months after post treatment.

Day -1 to 24 months post treatment

次要结果测量

结果测量
措施说明
大体时间
Rate and severity of ICANS as per ASTCT
大体时间:30 days

Assessed using American Society for Transplantation and Cellular Therapy (ASTCT). The rate and severity of immune cell associated neurotoxicity syndrome (ICANS) within the first 30 days of infusion.

30 days
Objective response rate (ORR)
大体时间:Day -1 to 24 months post treatment

The incidence of either a complete response or a partial response by Lugano. All subjects that do not meet the criteria for an objective response by the analysis data cutoff date will be considered non-responders.

Day -1 to 24 months post treatment

其他结果措施

结果测量
措施说明
大体时间
Duration of response (DOR)
大体时间:From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

Among subject who experience an objective response the date of their first objective response to disease progression per Lugano or death regardless of cause. Subjects not meeting the criteria for progression or death by the analysis data cutoff date will be censored at their last evaluable disease assessment date and their response will be noted as ongoing.

From First Objective Response until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Progression-free Survival (PFS)
大体时间:From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment

The time from the CAR-T infusion date to the date of disease progression per Lugano or death from any cause. Subjects not meeting the criteria for progression by the analysis data cutoff date will be censored at their last evaluable disease assessment date.

From Day 0 until date of first documented disease progression or date of death from any cause, assessed up to 24 months post treatment
Overall survival (OS)
大体时间:From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

The time from CAR-T infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at their last contact date.

From Day 0 until documented date of death from any cause, assessed up to 24 months post treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Matthew Frigault, MD、Massachusetts General Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年9月18日

初级完成 (估计的)

2027年8月1日

研究完成 (估计的)

2028年8月1日

研究注册日期

首次提交

2024年8月5日

首先提交符合 QC 标准的

2024年8月8日

首次发布 (实际的)

2024年8月12日

研究记录更新

最后更新发布 (实际的)

2026年10月6日

上次提交的符合 QC 标准的更新

2026年10月1日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

IPD 共享时间框架

Data can be shared no earlier than 1 year following the date of publication

IPD 共享访问标准

Contact the Partners Innovations team at http://www.partners.org/innovation

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅